Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insulet Corp (PODD)

Insulet Corp (PODD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Insulet Corp 100 NAGOG PARK ACTON MA 01720 USA

www.insulet.com Employees: 3,900 P: 978-600-7000

Sector:

Medical

Description:

Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas.

Key Statistics

Overview:

Market Capitalization, $K 19,996,136
Enterprise Value, $K 20,422,636
Shares Outstanding, K 70,347
Float, K 70,073
% Float 99.61%
Short Interest, K 2,070
Short Float 2.94%
Days to Cover 3.45
Short Volume Ratio 0.40
% of Insider Shareholders 0.39%

Financials:

Annual Sales, $ 2,072 M
Annual Net Income, $ 418,300 K
Last Quarter Sales, $ 706,300 K
Last Quarter Net Income, $ 87,600 K
EBIT, $ 436,900 K
EBITDA, $ 517,700 K

Growth:

1-Year Return 3.93%
3-Year Return -0.44%
5-Year Return 6.39%
5-Year Revenue Growth 180.63%
5-Year Earnings Growth 1,605.26%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.24 on 11/06/25
Next Earnings Date 02/18/26
Earnings Per Share ttm 4.58
EPS Growth vs. Prev Qtr 5.98%
EPS Growth vs. Prev Year 37.78%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

PODD Ratios

Ratio
Price/Earnings ttm 62.82
Price/Earnings forward 46.56
Price/Earnings to Growth 1.60
Return-on-Equity % 24.36%
Return-on-Assets % 10.02%
Profit Margin % 20.19%
Debt/Equity 0.73
Price/Sales 8.20
Price/Cash Flow 64.85
Price/Book 14.62
Book Value/Share 19.67
Interest Coverage 8.03
60-Month Beta 1.40
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar